On March 28, 2024, GenFleet Therapeutics (Shanghai), Inc. ("GenFleet"), SELLAS Life Science Group Inc.'s partner with respect to the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, announced that it entered into a clinical trial collaboration and supply agreement with BeiGene Switzerland GmbH to initiate a combination study of GFH009 and BRUKINSA® (zanubrutinib, BTK inhibitor) in a multicenter phase Ib/II trial treating diffuse large B-cell lymphoma (DLBCL) and announced the dosing of the first patient in the trial. According to the announcement, under the terms of the clinical trial collaboration and supply agreement, GenFleet will conduct an open-label, single-arm and multi-center study of the combination therapy to evaluate the safety and efficacy among relapsed/refractory DLBCL patients. The study is being conducted in China.

The information in this Item 8.01 is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.